Economic Evaluations of Strategies for Preventing Renal Disease in Non-Insulin Dependent Diabetes Mellitus
Recent clinical trials such as the Stockholm Diabetes Intervention Study (SDIS) and the Diabetes Control and Complications Trial (DCCT) have demonstrated that intensive glycaemic control can slow the development and delay the progression of renal disease in persons with insulin dependent diabetes mellitus (IDDM) [1,2]. In addition, clinical studies suggest that treatment of patients with microalbuminuria and clinical nephropathy with angiotensin-converting enzyme (ACE) inhibitors and other antihypertensive agents [3–8] or with a low protein diet [9–12] can slow progression to end-stage renal disease. However, few studies have demonstrated the efficacy of such interventions in persons with non-insulin dependent diabetes mellitus (NIDDM).
KeywordsEconomic Evaluation Diabetic Nephropathy Health Care Financing NIDDM Patient Intervention Cost
Unable to display preview. Download preview PDF.
- 17.Siegel JE, Krolewski AS, Warram JH, Weinstein MC. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol 1992; 3: S111–S119.Google Scholar
- 28.United States Renal Data System. USRDS 1993 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1993.Google Scholar
- 29.Health Care Financing Administration. Research Report: End Stage Renal Disease, 1991. HCFA Publ. No. 03338. Baltimore, MD: Health Care Financing Administration; 1993.Google Scholar
- 30.Health Care Financing Administration. List of Top 200 Procedure Codes Ranked by Allowed Charges from the Completed Year 1990. Baltimore, MD: Health Care Financing Administration; 1992.Google Scholar
- 31.Medicare Fee Schedule. Federal Register, November 25, 1992; 57: 55896–56230.Google Scholar